The use of biological therapy in refractory rheumatic diseases other than rheumatoid arthritis: experience at a tertiary care center in Lebanon.
Musallam
Khaled M
KM
Arayssi
Thurayya
T
Taher
Ali T
AT
Kanj
Nadim
N
Uthman
Imad
I
D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000628:therapy*; D001691:Biological Therapy; D005260:Female; D006784:Hospitals, Teaching; D006801:Humans; D000069285:Infliximab; D007861:Lebanon; D008297:Male; D016032:Randomized Controlled Trials as Topic; D012216:Rheumatic Diseases / Q000628:therapy*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000069283:Rituximab; D000069285:Infliximab